Piper Jaffray Cos. reaffirmed their overweight rating on shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) in a report released on Friday morning. They currently have a $38.00 price objective on the stock.
AIMT has been the topic of several other reports. Credit Suisse Group AG reaffirmed a buy rating and issued a $35.00 target price on shares of Aimmune Therapeutics in a research report on Friday, August 19th. Wedbush reaffirmed a buy rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a research report on Wednesday, August 24th. Finally, Zacks Investment Research raised Aimmune Therapeutics from a sell rating to a hold rating in a research report on Monday, September 19th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $32.20.
Shares of Aimmune Therapeutics (NASDAQ:AIMT) opened at 15.49 on Friday. Aimmune Therapeutics has a 52-week low of $9.77 and a 52-week high of $26.50. The company has a 50 day moving average of $14.91 and a 200 day moving average of $13.60. The stock’s market capitalization is $654.51 million.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.01. Analysts predict that Aimmune Therapeutics will post ($1.75) EPS for the current fiscal year.
In other news, insider Mary M. Rozenman sold 30,000 shares of the firm’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $16.80, for a total transaction of $504,000.00. Following the transaction, the insider now directly owns 30,000 shares of the company’s stock, valued at $504,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 24.56% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Nationwide Fund Advisors raised its position in shares of Aimmune Therapeutics by 127.7% in the second quarter. Nationwide Fund Advisors now owns 16,929 shares of the company’s stock worth $183,000 after buying an additional 9,495 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Aimmune Therapeutics by 150.5% in the second quarter. JPMorgan Chase & Co. now owns 105,975 shares of the company’s stock valued at $1,147,000 after buying an additional 63,675 shares in the last quarter. Emerald Acquisition Ltd. purchased a new position in shares of Aimmune Therapeutics during the second quarter valued at $154,000. Swiss National Bank boosted its position in shares of Aimmune Therapeutics by 41.3% in the second quarter. Swiss National Bank now owns 31,474 shares of the company’s stock valued at $341,000 after buying an additional 9,200 shares in the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of Aimmune Therapeutics by 133.9% in the second quarter. California State Teachers Retirement System now owns 55,115 shares of the company’s stock valued at $596,000 after buying an additional 31,555 shares in the last quarter. 68.87% of the stock is currently owned by institutional investors.
About Aimmune Therapeutics
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.